Our results broaden the knowledge that TIGIT could not only express on immune cells, but also on cancer cells, and this intrinsic expression may deliver inhibitory signals through the interaction with PVR on CD8+ T cells and NK cells. The gene discussed is PVR; the disease is cancer.